Literature DB >> 24065533

The HTLV-1 HBZ protein inhibits cyclin D1 expression through interacting with the cellular transcription factor CREB.

Yunyun Ma1, Shangen Zheng, Yuanyuan Wang, Wenqiao Zang, Min Li, Na Wang, Ping Li, Jing Jin, Ziming Dong, Guoqiang Zhao.   

Abstract

Human T cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus that can cause adult T-cell leukemia (ATL) and other diseases. The HTLV-1 bZIP factor (HBZ), which is encoded by an mRNA of the opposite polarity of the viral genomic RNA, interacts with several transcription factors and is involved in T cell proliferation, viral gene transcription and cellular transformation. Cyclin D1 is a pivotal regulatory protein involved in cell cycle progression, and its depressed expression correlates with cell cycle prolongation or arrested at the G1/S transition. In our present study, we observed that HBZ expression suppressed cyclin D1 level. To investigate the role of HBZ on cyclin D1 depression, we transduced HBZ with lentivirus vector into 293T cells, CEM cells and Jurkat cells. The results of Western blot, RT-PCR and luciferase assays showed that transcriptional activity of the cyclin D1 promoter was suppressed by the bZIP domain of HBZ (HBZ-bZIP) through cyclic AMP response element (CRE) site. Immunoprecipitation and GST pull-down assays showed the binding of HBZ-bZIP to CRE-binding protein (CREB), which confirmed that the cyclin D1 promoter activity inhibition via the CRE-site was mediated by HBZ-bZIP. The results suggested that HBZ suppressed cyclin D1 transcription through interactions with CREB and along with other viral protein, HBZ may play a causal role for leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065533     DOI: 10.1007/s11033-013-2706-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  57 in total

1.  Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker.

Authors:  Takao Kinjo; Julia Ham-Terhune; Jean-Marie Peloponese; Kuan-Teh Jeang
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

Review 2.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

3.  Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway.

Authors:  D Joyce; B Bouzahzah; M Fu; C Albanese; M D'Amico; J Steer; J U Klein; R J Lee; J E Segall; J K Westwick; C J Der; R G Pestell
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

4.  pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.

Authors:  R J Lee; C Albanese; R J Stenger; G Watanabe; G Inghirami; G K Haines; M Webster; W J Muller; J S Brugge; R J Davis; R G Pestell
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

5.  HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes.

Authors:  Koichiro Suemori; Hiroshi Fujiwara; Toshiki Ochi; Taiji Ogawa; Masao Matsuoka; Tadashi Matsumoto; Jean-Michel Mesnard; Masaki Yasukawa
Journal:  J Gen Virol       Date:  2009-05-07       Impact factor: 3.891

6.  Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I.

Authors:  Hideki Hasegawa; Hirofumi Sawa; Martha J Lewis; Yasuko Orba; Noreen Sheehy; Yoshie Yamamoto; Takeshi Ichinohe; Yasuko Tsunetsugu-Yokota; Harutaka Katano; Hidehiro Takahashi; Junichiro Matsuda; Tetsutaro Sata; Takeshi Kurata; Kazuo Nagashima; William W Hall
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

7.  HBZ interacts with JunD and stimulates its transcriptional activity.

Authors:  Sabine Thébault; Jihane Basbous; Patrick Hivin; Christian Devaux; Jean-Michel Mesnard
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

8.  HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo.

Authors:  Yorifumi Satou; Jun-Ichirou Yasunaga; Tiejun Zhao; Mika Yoshida; Paola Miyazato; Ken Takai; Kei Shimizu; Koichi Ohshima; Patrick L Green; Naganari Ohkura; Tomoyuki Yamaguchi; Masahiro Ono; Shimon Sakaguchi; Masao Matsuoka
Journal:  PLoS Pathog       Date:  2011-02-10       Impact factor: 6.823

9.  The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription.

Authors:  Y-M Kim; T R Geiger; D I Egan; N Sharma; J K Nyborg
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

10.  HTLV-I antisense transcripts initiating in the 3'LTR are alternatively spliced and polyadenylated.

Authors:  Marie-Hélène Cavanagh; Sébastien Landry; Brigitte Audet; Charlotte Arpin-André; Patrick Hivin; Marie-Eve Paré; Julien Thête; Eric Wattel; Susan J Marriott; Jean-Michel Mesnard; Benoit Barbeau
Journal:  Retrovirology       Date:  2006-03-02       Impact factor: 4.602

View more
  4 in total

Review 1.  Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence.

Authors:  Alexandre Carpentier; Pierre-Yves Barez; Malik Hamaidia; Hélène Gazon; Alix de Brogniez; Srikanth Perike; Nicolas Gillet; Luc Willems
Journal:  Viruses       Date:  2015-07-07       Impact factor: 5.048

Review 2.  The Role of HBZ in HTLV-1-Induced Oncogenesis.

Authors:  Tiejun Zhao
Journal:  Viruses       Date:  2016-02-02       Impact factor: 5.048

Review 3.  Molecular Studies of HTLV-1 Replication: An Update.

Authors:  Jessica L Martin; José O Maldonado; Joachim D Mueller; Wei Zhang; Louis M Mansky
Journal:  Viruses       Date:  2016-01-27       Impact factor: 5.048

Review 4.  The bZIP Proteins of Oncogenic Viruses.

Authors:  Madeleine L Stolz; Craig McCormick
Journal:  Viruses       Date:  2020-07-14       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.